We treat our patients according to current treatment protocols and schemes valid within the framework of pan-European or worldwide recommended procedures.

Many of our doctors are members of international committees and commissions for clinical trials in the treatment of childhood tumors, leukemias and non-cancerous blood diseases.

Our workplace is actively involved in the development of diagnosis and treatment of childhood malignancies in Europe.

• We treat children with all types of cancerous tissues and organs, so-called solid tumors.

• We provide comprehensive care for children with leukemia and others blood cancer.

• We care for children with non-cancer hematopoietic disease.

• We take care of children with blood clotting disorder.

It is also part of the comprehensive care for our patients and their families psychological counseling and the work of a game therapist. We allow families to consult social workers, we work together Elementary school and Kindergarten FN Motol.

The Department of Pediatric Hematology and Oncology is appointed the European Reference Center for the Diagnosis and Treatment of Tumors in Children. It is part of a network of European reference centers European Reference Network (ERN) defined by the European Directive (2011/24 / EU Directive on Patients' Rights in Cross-border Healthcare.

The aim of this initiative is to provide comparable and the best possible healthcare to children with cancer, regardless of where the patient lives in Europe.

ERN brings together doctors and scientists who are experts in rare or less common complex diseases. Together, they create "virtual networks" in which they discuss diagnoses and the most appropriate possible diagnostic and treatment procedures.

Members use a dedicated information platform to discuss and share data with patients (Clinical Patient Management System, CMPS). This platform enables, with the consent of the patient and in accordance with European data protection regulations, the sharing of clinical information, imaging documentation from imaging methods, histological specimens, laboratory tests and together the experts of the association in the ERN to propose the best procedure for the patient.

The experts of the association in the ERN network also participate in joint coordinated research, create guidelines for clinical care and organize training for healthcare professionals. More information about this activity can be found on the website www.expornet.eu

Most children with leukemia, lymphomas, histiocytosis, brain tumors, embryonic tumors (neuroblastoma, nephroblastoma, hepatoblastoma), sarcomas (Ewing's sarcoma, osteosarcoma, soft tissue sarcomas) are treated at the Department of Pediatric Hematology and Oncology 2.LF and FN Motol in academic treatment optimizing international studies. These are medical procedures organized by pediatric oncologists working in university hospitals and implemented in international cooperation. Part of the treatment protocol may take the form of a randomized study in which two (or more) treatments are objectively compared. Treatment in the standard arm of the study is the best current treatment standard, treatment in the experimental arm should be as good or better. The reason for randomization is an objective evaluation of the patient's response to treatment without undue medical expectations.

Prospective randomized clinical trials are currently the best available technology for objectively evaluating the efficacy and safety of drugs and treatments, providing patients with the best quality of care (diagnosis verification in reference laboratories, response verification, toxicity monitoring). Participation in clinical trials improves treatment outcomes - more accurate adherence to the protocol - drug doses, intervals between them, centrally verified diagnosis in specialized laboratories, controlled course of treatment and response, monitoring of toxic complications, the possibility of consulting complicated cases with the study. The studies are monitored by groups of independent experts.

Cancer is a rare disease in children, academic clinical trials conducted in international collaboration to accelerate statistically evaluable results have a more than 40-year tradition in pediatric oncology, and treatment of children with tumors in clinical trials, if available, has become pediatric oncology. norm. Clinical studies have defined standards of diagnosis, surgery, radiation, radiotherapy, chemotherapy for individual tumors. However, clinical trials are usually not available for rare tumors of childhood because a very small number of patients do not allow their real-time implementation. Their treatment follows recommended procedures based on published experience.

In November 2020, the Department of Pediatric Hematology and Oncology was accepted into an international consortium of centers implementing innovative treatment of resistant and relapsing leukemias, lymphomas, brain tumors and solid tumors. The consortium is called ITCC (Innovative Therapies for Children with Cancer) and organizes treatment studies using new drugs in children with advanced disease that do not respond to standard treatment. The ITCC website has the address: www.itcc-consortium.org

Highly specialized modern diagnostics of genes and cell pathways involved in tumor formation is used where possible for individualized targeted treatment of selected tumors. The Department of Pediatric Hematology and Oncology diagnoses these changes in leukemias and lymphomas, brain tumors and solid tumors in its own research laboratories - website: https://clip.lf2.cuni.cz/cs/, cooperation with the Institute of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and selected tumors are analyzed in laboratories in Heidelberg as part of the study INFORMATION (INindividualized Theraps FOr Relapsed Malignments in childhood), https://www.kitz-heidelberg.de/en/for-physicians/clinical-studies/molecular-diagnostics-studies/inform/, in which the clinic is involved.

23.11.2020/XNUMX/XNUMX Prof. MUDr. Jan Starý, DrSc.